However, the overall response rates of anti-PD-1 or anti-PDL1 mAb therapy were reported to be less than 40%.39 In this study, we identified EREG as a key regulator of PDL1 expression in HNSCC. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.